The Promise and Reality of ctDNA in Early-Stage Breast Cancer
The quest for a “liquid biopsy” that can detect cancer recurrence long before a scan can see it has led to the rise of circulating tumor DNA (ctDNA) testing. For patients with early-stage breast cancer, the ability to monitor minimal residual disease (MRD) offers a tantalizing possibility: the ability to escalate treatment for those at high risk or de-escalate it for those who are clear.
However, a critical gap remains between a test’s ability to predict an outcome and its ability to improve one. While ctDNA is showing strong prognostic signals, medical experts warn that it is not yet ready for routine clinical use to guide treatment decisions.
- Prognostic vs. Clinical Utility: ctDNA can predict the likelihood of recurrence (prognosis), but there is no evidence yet that changing treatment based on these results improves patient survival (clinical utility).
- The Risk of Over-Treatment: Intervening based on a positive ctDNA test without trial evidence risks exposing patients to unnecessary treatment-related harm.
- The Evidence Gap: Most current data comes from retrospective studies; prospective interventional trials are required to validate the technology.
Understanding ctDNA: The Science of Liquid Biopsies
Circulating tumor DNA (ctDNA) consists of slight fragments of DNA shed by tumor cells into the bloodstream. In early-stage breast cancer, these tests are used to look for “minimal residual disease”—microscopic amounts of cancer that remain after primary surgery or chemotherapy.
The goal is to identify patients who are “ctDNA-positive” after initial treatment, which suggests a higher risk of distant recurrence. In theory, these patients could benefit from more aggressive adjuvant therapies, while “ctDNA-negative” patients might safely avoid toxic treatments they don’t need.
Prognosis vs. Clinical Utility: Why the Distinction Matters
In oncology, there is a fundamental difference between a prognostic association and clinical utility. This distinction is the primary reason why ctDNA is not yet standard of care for guiding therapy.
- Prognostic Association: This means the test is excellent at predicting what will happen. Multiple retrospective data sets show a strong link between the presence of ctDNA and the eventual recurrence of cancer.
- Clinical Utility: This means acting on the test result actually changes the patient’s outcome for the better. To prove clinical utility, a trial must demonstrate that treating a ctDNA-positive patient (who might otherwise have remained asymptomatic) leads to better survival rates than standard care.
Dr. Heather A. Parsons, Program Head of Breast Oncology at the Fred Hutch Cancer Center and University of Washington, emphasized this distinction at the 43rd Annual Miami Breast Cancer Conference. She noted that while the prognostic associations are compelling, no interventional trial has yet proven that acting on these results improves patient outcomes.
The Cautionary Tale of Biomarker Over-Reliance
The push for rapid adoption of ctDNA is tempered by history. Dr. Parsons pointed to the SWOG S0500 trial as a cautionary example. That study examined whether switching chemotherapy in patients with metastatic breast cancer based on circulating tumor cell (CTC) status would improve outcomes. The results served as a reminder that a biological signal does not always translate into a clinical win.
The danger of conflating prognosis with utility is that it may lead clinicians to intervene too early or incorrectly, potentially causing treatment-related harm without a guaranteed benefit to the patient.
The Path Forward: What Needs to Happen?
The medical community is optimistic that ctDNA will eventually play a key role in precision oncology. However, the transition from “promising” to “proven” requires several milestones:
- Prospective Interventional Trials: Researchers must conduct trials where treatment is randomized based on ctDNA results to see if outcomes actually improve.
- Safety Data on De-escalation: Evidence is needed to prove that stopping therapy based on a negative ctDNA test is safe and does not increase the risk of recurrence.
- Technological Convergence: The arrival of ultrasensitive detection platforms must be matched with treatments that are effective enough to make early intervention worthwhile.
Frequently Asked Questions
Can I ask my doctor for a ctDNA test today?
While some labs offer these tests, they are currently viewed as prognostic tools rather than guides for changing treatment. Most clinicians advise caution until interventional trial data is available.
Does a positive ctDNA test mean the cancer has returned?
Not necessarily. A positive test indicates a higher risk of recurrence, but it does not always correlate with a visible tumor on a scan. This “lead time” is why the technology is exciting, but also why it is dangerous to treat without a proven protocol.
Will ctDNA replace traditional imaging like CT or PET scans?
It is unlikely to replace imaging entirely. Instead, it is envisioned as a complementary tool that could provide a more sensitive “early warning system” alongside traditional radiology.
Final Outlook: ctDNA represents a potential inflection point in breast cancer care. However, the transition from retrospective promise to clinical practice requires rigorous validation. Until interventional trials confirm that acting on these signals saves lives, the technology remains a powerful prognostic indicator rather than a clinical roadmap.